Kester Capital

Venture Capital

Kester Capital is a mid-market private equity firm that invests in high potential, innovative life science companies.

Portfolio

companies

Portfolio companies

Optibrium

Optibrium provides software and artificial intelligence platforms for drug discovery.

Team

Adam Maidment

Managing Partner

Adam serves as managing partner at Kester Capital and holds multiple non-executive director roles across various companies.

Recent investments

Seed21 June 2022

£21

Optibrium secures seed investment from Kester Capital to fund expansion

Kester Capital provides further backing to accelerate the development of computer-aided drug discovery technologies.

"It’s been an incredible year, with Kester Capital’s original investment affording us the opportunity to take the company to new heights as we successfully launched Cerella, our ground-breaking new AI platform, and actioned ambitious plans to grow the company. I am delighted that due to this success, Kester is investing further and their continued support will allow us to accelerate our product development plans and further capitalise on the substantial market opportunities."

— Matt Segall, CEO

Optibrium—Cambridge, UK

Kester Capital

Growth10 February 2021

£15.0M

Optibrium secures growth private equity investment from Kester Capital to advance drug discovery software

Kester Capital has backed Cambridge-based Optibrium to drive commercial expansion and product development.

"Optibrium is a cutting edge software business that is driving some of the most exciting developments within computer-aided drug discovery. We had been tracking the business for some time and were really impressed by the team and the business’ achievements. We are looking forward to working with Matt and Ed to grow the business."

— Adam Maidment, Managing Partner

Optibrium—Cambridge, UK

Kester Capital